Novartis Ag (NVS) EBITDA (2009 - 2025)
Novartis Ag recorded quarterly EBITDA of $4.9 billion in Q2 2025, down 34.15% quarter-over-quarter from $7.4 billion in Q4 2024, and up 21.18% year-over-year from $4.0 billion in Q2 2024.
Novartis Ag's EBITDA history runs 16 years deep, the most recent figure standing at $4.9 billion for Q2 2025.
- In Q2 2025, EBITDA rose 21.18% year-over-year to $4.9 billion; the TTM figure through Jun 2025 stood at $21.7 billion (up 39.63% YoY), while the FY2025 annual figure was $17.6 billion, up 21.31% from the prior year.
- EBITDA came in at $4.9 billion for Q2 2025 at Novartis Ag, down from $7.4 billion in the prior quarter.
- In the past five years, EBITDA ranged from a high of $7.4 billion in Q4 2024 to a low of $273.0 million in Q4 2022.
- A 5-year average of $2.9 billion and a median of $2.2 billion in 2021 frame the typical range for EBITDA.
- Across the five-year window, EBITDA surged 1887.18% in 2023 and plunged 30.51% in 2024, its largest moves.
- Novartis Ag's EBITDA stood at $386.0 million in 2021, then slipped by 29.27% to $273.0 million in 2022, then soared by 1887.18% to $5.4 billion in 2023, then surged by 36.17% to $7.4 billion in 2024, then sank by 34.15% to $4.9 billion in 2025.
- According to Business Quant data, EBITDA over the past three periods registered $4.9 billion, $7.4 billion, and $4.0 billion for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.83 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.86 Bn |
| Dec 31, 2024 | 7.39 Bn |
| Jun 30, 2024 | 4.01 Bn |
| Dec 31, 2023 | 5.43 Bn |
| Jun 30, 2023 | 5.78 Bn |
| Mar 31, 2023 | 319.00 Mn |
| Dec 31, 2022 | 273.00 Mn |
| Sep 30, 2022 | 377.00 Mn |
| Jun 30, 2022 | 4.69 Bn |
| Mar 31, 2022 | 394.00 Mn |
| Dec 31, 2021 | 386.00 Mn |
| Sep 30, 2021 | 440.00 Mn |
| Jun 30, 2021 | 5.58 Bn |
| Mar 31, 2021 | 312.00 Mn |
| Dec 31, 2020 | 372.00 Mn |
| Sep 30, 2020 | 395.00 Mn |
| Jun 30, 2020 | 5.14 Bn |
| Mar 31, 2020 | -45.00 Mn |
| Mar 31, 2019 | 273.00 Mn |
| Dec 31, 2018 | 237.00 Mn |
| Sep 30, 2018 | 358.00 Mn |
| Jun 30, 2018 | 2.48 Bn |
| Mar 31, 2018 | 409.00 Mn |
| Dec 31, 2017 | 305.00 Mn |
| Sep 30, 2017 | 390.00 Mn |
| Jun 30, 2017 | 2.28 Bn |
| Mar 31, 2017 | 343.00 Mn |
| Dec 31, 2016 | 7.53 Bn |
| Sep 30, 2016 | 354.00 Mn |
| Jun 30, 2016 | 380.00 Mn |
| Mar 31, 2016 | 346.00 |
| Dec 31, 2015 | 216.00 Mn |
| Sep 30, 2015 | 0.00 |
| Mar 31, 2015 | 340.00 |
| Dec 31, 2014 | 365.00 |
| Sep 30, 2014 | 381.00 |
| Mar 31, 2014 | 674.00 |
| Sep 30, 2012 | 360.00 |
| Jun 30, 2012 | 419.00 |
| Mar 31, 2012 | 363.00 |
| Dec 31, 2011 | 331.00 |
| Sep 30, 2011 | 341.00 |
| Jun 30, 2011 | 371.00 |
| Mar 31, 2011 | 524.00 |
| Dec 31, 2010 | 308.00 |
| Sep 30, 2010 | 430.00 |
| Jun 30, 2010 | 294.00 |
| Mar 31, 2010 | 3,511.00 |
| Dec 31, 2009 | 11,437.00 |
| Sep 30, 2009 | 2,634.00 |
| Jun 30, 2009 | 271.00 |
| Mar 31, 2009 | 2,347.00 |